DMG-PEG2000-NH2: NH2-PEG Derivative for Liposomal Drug Delivery

Executive Summary: DMG-PEG2000-NH2 is a high-purity, amine-functionalized polyethylene glycol (PEG) derivative used as a biocompatible linker in lipid-based drug delivery systems (APExBIO). This reagent exhibits excellent solubility in DMSO (≥51.6 mg/mL), ethanol (≥52 mg/mL), and water (≥25.3 mg/mL) and supports efficient amide bond formation with carboxyl-containing biomolecules. Its primary application is in the assembly of lipid nanoparticles (LNPs) and liposomes for nucleic acid and protein encapsulation, with documented enhancements in stability and biocompatibility of conjugates. Quality control data, including COA and MSDS, ensure batch reproducibility and user safety (Chen et al., 2021). APExBIO supplies this product as SKU M2006, with a purity >90% and recommended storage at −20°C.

Biological Rationale

Polyethylene glycol (PEG) derivatives are widely used to improve the pharmacokinetics and biocompatibility of therapeutic agents. The addition of a primary amine group (–NH2) to PEG chains, as in DMG-PEG2000-NH2, enables covalent attachment to carboxylic acid-containing biomolecules through amide bond formation (APExBIO). This process, known as PEGylation, increases the solubility, reduces immunogenicity, and prolongs the circulation time of drugs and bioconjugates (DSG-PEG2000 Article). Lipid nanoparticles (LNPs) and liposomes formulated with NH2-PEG derivatives demonstrate improved encapsulation efficiency for nucleic acids, such as siRNA, and enhanced formulation stability. The use of PEG linkers also minimizes nonspecific protein binding and clearance by the mononuclear phagocyte system (MPS), supporting targeted delivery strategies.

Mechanism of Action of DMG-PEG2000-NH2

DMG-PEG2000-NH2 features a PEG chain (average molecular weight 2000 Da) terminated with a 1,2-dimyristoyl-sn-glycerol (DMG) lipid anchor and a primary amine group. The amine group reacts selectively with activated carboxyl groups (e.g., NHS-esters) via nucleophilic substitution to form stable amide bonds under mild aqueous or organic conditions (typically pH 7–9, 4–25°C, 1–4 hours) (Chen et al., 2021). This reaction is central to bioconjugation strategies for proteins, peptides, and oligonucleotides. The lipophilic DMG moiety enables integration into lipid bilayers, facilitating the construction of LNPs and liposomes. The PEG segment provides a hydrophilic corona, reducing aggregation and opsonization. This dual functionality supports both structural stability and biological stealth in vivo (DMG-PEG2000-NH2: Bridging Molecular Design).

Evidence & Benchmarks

• DMG-PEG2000-NH2 demonstrates solubility ≥51.6 mg/mL in DMSO, ≥52 mg/mL in ethanol, and ≥25.3 mg/mL in water at 20°C, facilitating compatibility with multiple formulation protocols (APExBIO).
• Amide bond formation with carboxylic acid–containing biomolecules proceeds efficiently at pH 7–9, 4–25°C, with >90% conversion in under 2 hours using standard EDC/NHS activation chemistry (Chen et al., 2021).
• LNPs formulated with DMG-PEG2000-NH2 display increased colloidal stability and reduced aggregation compared to non-PEGylated controls (dynamic light scattering, 25°C, pH 7.4) (Optimizing Liposomal Drug Delivery Linkers).
• siRNA encapsulation efficiency in LNPs using DMG-PEG2000-NH2 exceeds 90% at an N/P ratio of 3, with particle sizes maintained at 80–120 nm (phosphate buffer, 4°C) (The NH2-PEG Derivative for Advanced LNP).
• DMG-PEG2000-NH2 is supplied at >90% purity with batch-specific COA and MSDS, ensuring reproducibility for regulated research and manufacturing (APExBIO).

Applications, Limits & Misconceptions

Key Applications

• Lipid Nanoparticle (LNP) Formulation: Used as a PEGylated linker to construct LNPs for siRNA and mRNA delivery.
• Liposomal Drug Delivery: Enhances stability, reduces aggregation, and increases circulation time of liposome-encapsulated therapeutics.
• Bioconjugation: Facilitates amide bond formation with carboxyl-containing proteins, peptides, and oligonucleotides.
• PEGylation: Improves solubility, reduces immunogenicity, and prolongs half-life of conjugated biomolecules.

This article extends previous analyses such as 'Bridging Molecular Design and Precision' by detailing new mechanistic and workflow integration insights, and updates the performance benchmarks from 'The NH2-PEG Derivative for Advanced LNP' by providing quantitative, condition-specific results.

Common Pitfalls or Misconceptions

• DMG-PEG2000-NH2 is not suitable for conjugation with non-carboxylated biomolecules without prior functionalization.
• The reagent is not designed for long-term storage in solution; stability decreases notably after several days, even at −20°C.
• It does not provide targeting capabilities; additional ligands must be conjugated for site-specific delivery.
• PEGylation may reduce cell uptake in some applications, requiring optimization of PEG density and length.
• Use outside recommended pH (7–9) or temperature range (4–25°C) can reduce amide bond formation efficiency and linker stability.

Workflow Integration & Parameters

For efficient conjugation, DMG-PEG2000-NH2 is typically dissolved in DMSO or water (≥25 mg/mL), then mixed with activated carboxyl-containing biomolecules (e.g., proteins, nucleic acids) in the presence of EDC/NHS or similar coupling agents. Reactions are performed at pH 7–9 and 4–25°C for 1–4 hours. LNP or liposome assembly utilizes thin-film hydration or ethanol injection methods, with the PEG-lipid incorporated at 1–5 mol% of total lipid content. Post-reaction, purification is achieved via dialysis or chromatography. The product should be stored at −20°C, protected from moisture and light, and solutions should be freshly prepared (APExBIO).

For detailed protocols and troubleshooting, see the manufacturer's guidelines and refer to 'Optimizing Liposomal Drug Delivery Linkers', which provides additional context on overcoming formulation bottlenecks. This article clarifies updated integration parameters and avoids procedural ambiguities seen in prior summaries.

Conclusion & Outlook

DMG-PEG2000-NH2, as supplied by APExBIO, is a validated, high-purity NH2-PEG derivative that enables precise and efficient bioconjugation for lipid nanoparticle and liposome drug delivery platforms. Its chemical design supports robust amide bond formation, streamlined workflow integration, and enhanced therapeutic encapsulation. Limitations include the need for compatible functional groups and careful storage practices. As PEGylated linker technology evolves, DMG-PEG2000-NH2 will continue to play a central role in advanced pharmaceutical research and formulation.